Home Metabolism PCSK9

PCSK9

Other Metabolism Related Inhibitors

Dehydrogenase Transferase DPP Aminopeptidase Procollagen C Proteinase P450 (e.g. CYP17) Phospholipase Factor Xa PDE DHFR
Cat.No. Product Name Information Product Use Citations Product Validations
S7976 SBC-115076 SBC-115076 is a potent extracellular proprotein convertase subtilisin kexin type 9 (PCSK9) antagonist.
Cancers (Basel), 2024, 16(4)713
Front Med (Lausanne), 2024, 11:1284199
Front Med (Lausanne), 2024, 11:1509168
E4629 AZD0780 AZD0780 (Laroprovstat, Pcsk9-IN-12) is an orally potent inhibitor of PCSK9 with a Kd value of <200 nM. It directly binds to PCSK9, blocks its function, and significantly reduces LDL cholesterol levels, making it useful for dyslipidemia research.
E1094New Enlicitide decanoate Enlicitide (MK‑0616) decanoate is an orally active macrocyclic peptide PCSK9 inhibitor that binds PCSK9, blocks its interaction with the low‑density lipoprotein receptor (LDLR), and thereby enhances hepatic clearance of LDL‑C. It reduces atherogenic lipoproteins, including non‑HDL cholesterol, apolipoprotein B, and lipoprotein(a) in hypercholesterolemic and HeFH patients.
S8420 R-IMPP R-IMPP is an inhibitor of PCSK9 secretion, half maximal inhibitory concentration [IC50] = 4.8 μM.
S0118 SBC-110736 SBC-110736 is an inhibitor of proprotein convertase subtilisin kexin type 9 (PCSK9) that lowers cholesterol levels in mice.
E0116 PF-06446846 hydrochloride PF-06446846 (PF846) Hydrochloride is an orally bioavailable and specific inhibitor of PCSK9 with an IC50 of 0.3 µM in Huh7 cells.
S0849 PF-06446846 PF-06446846 is an orally active proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. This compound selectively inhibits translation of PCSK9 by stalling the 80S ribosome in the proximity of codon region.